These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6151203)

  • 1. Information processing and neuroleptic response in acute and stabilized schizophrenic patients.
    Marder SR; Asarnow RF; Van Putten T
    Psychiatry Res; 1984 Sep; 13(1):41-9. PubMed ID: 6151203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
    Asarnow RF; Marder SR; Mintz J; Van Putten T; Zimmerman KE
    Arch Gen Psychiatry; 1988 Sep; 45(9):822-6. PubMed ID: 3046554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 9. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluphenazine decanoate: a clinical problem?
    Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
    Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia.
    Baron M; Gruen R; Levitt M; Kane J
    Neuropsychobiology; 1982; 8(6):312-4. PubMed ID: 6131392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
    Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 16. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
    Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
    Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study.
    Babin SL; Hood AJ; Wassef AA; Williams NG; Patel SS; Sereno AB
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1753-64. PubMed ID: 21689713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol.
    Classen W; Laux G
    Neuropsychobiology; 1989; 21(3):131-40. PubMed ID: 2575719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.